ES2564092T3 - Exotoxinas de pseudomonas mutadas con antigenicidad reducida - Google Patents

Exotoxinas de pseudomonas mutadas con antigenicidad reducida Download PDF

Info

Publication number
ES2564092T3
ES2564092T3 ES10179539.1T ES10179539T ES2564092T3 ES 2564092 T3 ES2564092 T3 ES 2564092T3 ES 10179539 T ES10179539 T ES 10179539T ES 2564092 T3 ES2564092 T3 ES 2564092T3
Authority
ES
Spain
Prior art keywords
essay
exotoxins
reduced antigenicity
amino acid
mutated pseudomonas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10179539.1T
Other languages
English (en)
Inventor
Ira H. Pastan
Masanori Onda
Satoshi Nagata
David Fitzgerald
Robert Kreitman
Byungkook Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2564092T3 publication Critical patent/ES2564092T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Exotoxina A de Pseudomonas ("PE") aislada, en la que dicha PE tiene una sustitución de alanina, glicina, serina o glutamina en lugar del resto aminoacídico E548, en la que el resto aminoacídico E548 se define en referencia a la secuencia de aminoácidos de la PE nativa (SEQ ID NO:1).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
los promotores T7, trp, lac o λ, un sitio de unión a ribosomas y preferentemente una señal de terminación de la transcripción. Para células eucariotas, las secuencias de control pueden incluir un promotor y preferentemente un potenciador derivado de genes de inmunoglobulinas, SV40, citomegalovirus y una señal de poliadenilación y pueden incluir secuencias donadoras y aceptoras de corte y empalme. Las casetes de la invención pueden transferirse a la
5 célula hospedadora elegida por procedimientos bien conocidos como la transformación por cloruro de calcio o la electroporación para E. coli y el tratamiento con fosfato de calcio, la electroporación o la lipofección para células de mamíferos. Las células transformadas con las casetes pueden seleccionarse por la resistencia a antibióticos conferida por genes contenidos en las casetes, como los genes amp, gpt, neo e hyg.
10 [00127] El experto reconocerá que es posible hacer modificaciones en un ácido nucleico que codifica un polipéptido de la presente invención (es decir, PE o un inmunoconjugado formado a partir de una PE de la invención) sin disminuir su actividad biológica. Algunas modificaciones pueden hacerse para facilitar la clonación, la expresión, o la incorporación de la molécula de reconocimiento en una proteína de fusión. Tales modificaciones son bien conocidas para los expertos en la técnica e incluyen, por ejemplo, codones de terminación, una metionina añadida al extremo
15 amino para proporcionar un sitio de iniciación, aminoácidos adicionales colocados en cualquiera de los extremos para crear sitios de restricción localizados convenientemente o aminoácidos adicionales (como poli-His) para facilitar las etapas de purificación.
[00128] Además de mediante procedimientos recombinantes, los inmunoconjugados y las PE de la presente
20 invención pueden construirse también en parte o en su totalidad mediante síntesis peptídica estándar. La síntesis en fase sólida de los polipéptidos de la presente invención de menos de 50 aminoácidos de longitud puede realizarse mediante la unión del aminoácido C-terminal de la secuencia a un soporte insoluble, seguida de la adición secuencial de los aminoácidos restantes de la secuencia. Las técnicas para la síntesis en fase sólida se describen en Barany y Merrifield, THE PEPTIDES: ANALYSIS, SYNTHESIS, BIOLOGY. Vol. 2: SPECIAL METHODS IN
25 PEPTIDE SYNTHESIS, parte A, págs. 3-284; Merrifield y col., J. Am. Chem. Soc. 85: 2149-2156 (1963) y Stewart y col., SOLID PHASE PEPTIDE SYNTHESIS, 2a edición, Pierce Chem. Co., Rockford, IL, EE. UU. (1984). Es posible sintetizar proteínas de mayor longitud por condensación de los extremos amino y carboxilo de fragmentos más cortos. Los procedimientos para formar enlaces peptídicos por activación de un extremo carboxilo terminal (p. ej., mediante el agente de acoplamiento N, N’-diciclohexilcarbodiimida) son conocidos para los expertos.
30
B. Purificación
[00129] Una vez expresados, los inmunoconjugados y PE recombinantes de la presente invención pueden purificarse según procedimientos estándar de la técnica, como precipitación con sulfato de amonio, columnas de
35 afinidad, cromatografía en columna y similares (véase generalmente R. Scopes, PROTEIN PURIFICATION, Springer-Verlag, NY, EE. UU. (1982). Se prefieren composiciones sustancialmente puras con una homogeneidad de al menos aproximadamente el 90-95% y una homogeneidad del 98 al 99% es la más preferida para usos farmacéuticos. Una vez purificados, parcialmente o hasta homogeneidad, según se desee, si han de usarse terapéuticamente, los polipéptidos no deberán contener sustancialmente ninguna endotoxina.
40 [00130] Los procedimientos para la expresión de anticuerpos de una sola cadena y/o su plegamiento para obtener una forma activa apropiada, incluidos los anticuerpos de una sola cadena de bacterias como E. coli , han sido descritos y son bien conocidos y aplicables a los anticuerpos de esta invención. Véase Buchner y col., Anal. Biochem. 205: 263-270 (1992); Pluckthun, Biotechniology 9: 545 (1991); Huse y col., Science 246: 1275 (1989) y
45 Ward y col., Nature 341: 544 (1989), todos ellos incorporados por referencia en este documento.
[00131] Frecuentemente, las proteínas heterólogas funcionales de E. coli o de otras bacterias se aíslan de cuerpos de inclusión y requieren la solubilización mediante desnaturalizantes fuertes y un subsiguiente plegamiento. Durante la etapa de solubilización, tal como es bien conocido en la técnica, debe haber presente un agente reductor para
50 separar los puentes disulfuro. Un tampón de ejemplo con un agente reductor es: Tris 0,1 M pH 8, guanidina 6 M, EDTA 2 mM, DTE (ditioeritritol) 0,3 M. La reoxidación de los puentes disulfuro puede tener lugar en presencia de reactivos tiólicos de bajo peso molecular en forma reducida y oxidada, tal como se describe en la publicación de Saxena y col., Biochemistry 9: 5015-5021 (1970), incorporada por referencia en este documento, y especialmente tal como describen Buchner y col., cita anterior.
55 [00132] Típicamente la renaturalización se consigue por dilución (p. ej., 100 veces) de la proteína desnaturalizada y reducida en el tampón de plegamiento. Un tampón de ejemplo es Tris 0,1 M pH 8,0, L-arginina 0,5 M, glutatión oxidado 8 mM y EDTA 2 mM.
20
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
Fusión Inmunización Refuerzo Ratón Título Procedimiento Número de final de cribado clones finales (c) 14 M1-ip x 4 D553E-ip C3H Hej 3 x 104 ICC con 0 CD30 15 M1-ipx3+ III-ip A/J 3x105 ICCcon30 3 D553E x 2 16 M1-ip x 3 + D553E-ip A/J 3 x 105 ICC con 13 D553E x 2 CD30
(c) Los clones se seleccionan por su alta afinidad relativa en ICC-ELISA con M40-3 como estándar. M1: M1(dsFv)-PE38, D553E: mutante de LMB-2 con D553E, R276G: mutante de M1(scFv)PE38 con R276G, III: dominio III
Tabla 2. Lista de MAb estudiados
Nombre
Epítopo Isotipo Título (log µl/µg) Afinidad (nM)
IP43
1a γ/I 2,6 0,10
IP62
1a γ/I 2,5 0,2
IP57
1a γ/I 1,9 0,00039
IP11
1b γ/I 2,6 6*
IP39
1b γ/I 2,8 0,93*
IP47
1b γ/I 2,8 0,47*
IP70
1b γ/I 2,5 58*
IP48
1b γ/I 2,7 3,3*
IP1
1b γ/I 2,6 5,80
IP35
1b γ/I 2,8 3,70
IP36
1b γ/I 2,6 3,60
IP42
1b γ/I 2,5 43
IP34
2a γ/I 2,7 0,11*
IP29
2b γ/I 2,8 20
IP63
2b γ/I 2,7 5
IP2
2b γ/I 2,7 0,30
IP15
2c γ/I 2,6 5,3
IP22
2c γ/I 2,6 3,4*
IP51
2c γ/I 2,2 3,10
IP76
2c γ/I 3,0 0,19
IP83
2c γ/I 2,5 0,43
IP9
3a γ/I 2,4 4,80
IP18
3a γ/I 2,5 0,09*
IP16
3a γ/I 2,5 0,24*
IP32
3a γ/I 2,7 33
IP44
3b γ/I 2,5 0,14
IP45
3b γ/I 2,9 0,47
IP58
3b γ/I 2,4 0,24
IP7
4a γ/I 2,7 0,04
IP10
4a γ/I 2,1 0,04
IP31
4a γ/I 2,9 0,27*
IP37
4a γ/I 2,7 1,40
IP49
4a γ/I 1,7 2,60
IP3
4a γ/I 2,6 0,00038
IP27
4a γ/I 2,7 16*
IP72
4a γ/I 2,8 4,4*
IP14
4b γ/I 2,6 81
IP82
4b γ/I 2,7 11*
IP86
4b γ/I 2,9 0,41*
IP13
5 γ/I 2,6 1,2
IP20
5 γ/I 2,3 0,1
29
imagen27
Tabla 4. CI50 de las inmunotoxinas preparadas por mutación de la PE en restos que afectan a la unión a diferentes epítopos
Ensay o n° 14
0,7
Ensay o n° 13
0,44
Ensay o n° 12
1,8
Ensay o n° 11
1,0
Ensay o n° 10
0,9 0,7 0,7
Ensay o n° 9
0,7 0,55 30 >100 0,4
Ensay o n° 8
2,0 1,9(?) 4,4 5,0/6,2
Ensay o n° 7
0,2 0,45
Ensay o n° 6
4 6 5 10
Ensay o n° 5
3,3 3,7 4,2 6,5
Ensay o n° 4
3,4 4,5
Ensay o n° 3
1,0 1,0
Ensay o n° 2
1,0 2,0 1,1 3,0
Ensay o n° 1
1,2ng/ml 3,0 0,72 0,72 1,5 2,1
N° de MAb bloqueados al mutar este resto
8 8 8 3 3 3 3 3/3 8 3 3 3
N° de MAb en este grupo epitópico
37 8 3 3 3 3/3 8 3 3 3
Epítopo
1 1 1 2c 5 2c 1/5/7 7 5/7 5/1 5/2/7 1 5 2 7
IT con los res tos designados mutados en la secuencia de la PE
InmunotoxinaHA22(control) N314A* N314S Q332A R467A R490A R538A* Q332A R490AK590A/K606A/613del* K590A R490AK590A* Q332AR490A* K606A* R490A R538AK590A* Q332S R490S* R538S* K590S
31 32
(continuación) */ La mutación redujo la citotoxicidad en más del 50%
Ensay o n° 14
0,9 0,8
Ensay o n° 13
0,7
Ensay o n° 12
1,0 0,8
Ensay o n° 11
0,75 0,6
Ensay o n° 10
0,8
Ensay o n° 9
Ensay o n° 8
Ensay o n° 7
Ensay o n° 6
Ensay o n° 5
Ensay o n° 4
Ensay o n° 3
Ensay o n° 2
Ensay o n° 1
N° de MAb bloqueados al mutar este resto
17 22 5
N° de MAb en este grupo epitópico
(5) 6
Epítopo
1/2c/5/7 3/1/2c/5/7 3/1/4a/2c/5/7 3/1/4a/2c/5/6/7 3/1/4a/2c/5/6/6/7
IT con los res tos designados mutados en la secuencia de la PE
Q332S R467AR490A K590S R313A Q332SR467A R490AK590S R313A Q332SR432G R467AR490A K590S R313A Q332SR432G R467AR490A R513AK590S R313A Q332SR432G R467AR490A R513AE548S K590S
imagen28
imagen29

Claims (1)

  1. imagen1
ES10179539.1T 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida Active ES2564092T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70379805P 2005-07-29 2005-07-29
US703798P 2005-07-29

Publications (1)

Publication Number Publication Date
ES2564092T3 true ES2564092T3 (es) 2016-03-17

Family

ID=37709138

Family Applications (6)

Application Number Title Priority Date Filing Date
ES10179539.1T Active ES2564092T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES15191388T Active ES2702650T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES15191395.1T Active ES2660026T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES10179520T Active ES2410783T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES15191391.0T Active ES2659039T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES06788523T Active ES2372537T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida.

Family Applications After (5)

Application Number Title Priority Date Filing Date
ES15191388T Active ES2702650T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES15191395.1T Active ES2660026T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES10179520T Active ES2410783T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES15191391.0T Active ES2659039T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida
ES06788523T Active ES2372537T3 (es) 2005-07-29 2006-07-25 Exotoxinas de pseudomonas mutadas con antigenicidad reducida.

Country Status (8)

Country Link
US (1) US8907060B2 (es)
EP (6) EP3006457B1 (es)
AT (1) ATE524489T1 (es)
AU (1) AU2006275865B2 (es)
CA (2) CA2941466C (es)
ES (6) ES2564092T3 (es)
PL (3) PL3006456T3 (es)
WO (1) WO2007016150A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989322B2 (en) 2007-02-07 2011-08-02 Micron Technology, Inc. Methods of forming transistors
WO2008109005A2 (en) * 2007-03-02 2008-09-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers
EP2197903B9 (en) 2007-09-04 2015-04-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
CA2773665C (en) * 2009-09-11 2018-02-20 Ira H. Pastan Improved pseudomonas exotoxin a with reduced immunogenicity
WO2011100455A1 (en) 2010-02-12 2011-08-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of antibody responses to foreign proteins
ES2678204T3 (es) 2010-07-30 2018-08-09 Medimmune, Llc Método para purificar inmunoconjugados
WO2012036746A1 (en) 2010-09-15 2012-03-22 Randall J Mrsny Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
WO2012145469A1 (en) 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
MX2013012905A (es) 2011-05-06 2014-04-25 Us Gov Health & Human Serv Inmunotoxina recombinante dirigida a la mesotelina.
KR20140033391A (ko) 2011-06-09 2014-03-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 면역원성이 보다 낮은 t 세포 및/또는 b 세포 에피토프를 갖는 슈도모나스 외독소 a
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
EP3301110A1 (en) 2011-09-16 2018-04-04 The USA, as represented by The Secretary, Department of Health and Human Services Pseudomonas exotoxin a with less immunogenic b cell epitopes
IN2014CN02906A (es) 2011-10-20 2015-07-03 Us Health
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2014031476A1 (en) 2012-08-21 2014-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
WO2014052064A1 (en) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
WO2014072306A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
JP6553515B2 (ja) 2012-12-20 2019-07-31 メディミューン，エルエルシー 免疫複合体の製造方法
CA2926215A1 (en) * 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
ES2764833T3 (es) 2013-10-11 2020-06-04 The United States Of America Represented By The Sec Dep Of Health And Human Services Anticuerpos contra TEM8 y su uso
EP3066118B1 (en) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
EP3102245B1 (en) 2014-02-05 2021-09-08 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
SG11201610183XA (en) 2014-05-07 2017-01-27 Applied Molecular Transp Llc Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
WO2016019280A1 (en) 2014-07-31 2016-02-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies against epha4 and their use
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
WO2017049296A1 (en) 2015-09-20 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
AU2016353067B2 (en) 2015-11-13 2023-10-05 Sanford Research Anti-BCMA polypeptides and proteins
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
US11066479B2 (en) 2016-08-02 2021-07-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
AU2017382883B2 (en) 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
US11390683B2 (en) 2017-05-18 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides and proteins
WO2018213064A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019055955A1 (en) 2017-09-18 2019-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN
KR20250174998A (ko) 2018-03-08 2025-12-15 어플라이드 몰레큘라 트랜스포트 인크. 경구 전달용 독소-유래 전달 구조체
WO2020014482A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
EP3833684A1 (en) 2018-08-08 2021-06-16 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
JP7487193B2 (ja) 2018-11-07 2024-05-20 アプライド モレキュラー トランスポート インコーポレイテッド 異種ペイロードの経口送達のためのコリックス由来担体
AU2020206308B2 (en) 2019-01-08 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
CA3125033A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
AU2020299382A1 (en) 2019-07-02 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind EGFRvIII and their use
CN114599665A (zh) 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化
US12552865B2 (en) 2019-10-22 2026-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting B7-H3 (CD276) for treating multiple solid tumors
WO2021097289A1 (en) 2019-11-15 2021-05-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pegylated recombinant immunotoxins
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
US20240075158A1 (en) 2020-12-22 2024-03-07 Jiangsu Hengrui Pharmaceutical Co., Ltd. Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
AU2022291120A1 (en) 2021-06-09 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
US20240417446A1 (en) 2021-10-26 2024-12-19 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
EP4448566A1 (en) 2021-12-17 2024-10-23 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
WO2024104584A1 (en) 2022-11-17 2024-05-23 University Of Cape Town Deimmunized pseudomonas exotoxin a
WO2024238346A1 (en) 2023-05-12 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
CN121986113A (zh) 2023-07-07 2026-05-05 美国政府(由卫生和人类服务部的部长所代表) 人源化40h3抗体
AU2024295016A1 (en) 2023-07-20 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
EP0531434B1 (en) 1990-05-11 1999-07-14 THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
EP0630234B1 (en) 1992-03-12 1997-06-11 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
AU675440B2 (en) 1992-06-18 1997-02-06 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant (pseudomonas) exotoxin with increased activity
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
JPH11515013A (ja) 1995-10-27 1999-12-21 メルク エンド カンパニー インコーポレーテッド 合成複合ワクチンの免疫原性担体としてのシュードモナスエクソトキシン
JP2001504334A (ja) * 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
US6296843B1 (en) 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
DE60039510D1 (de) * 1999-05-27 2008-08-28 Us Gov Health & Human Serv Immunokonjugate mit hoher bindungsaffinität
CA2404763A1 (en) 1999-11-11 2001-05-17 Raj K. Puri Mutated il-13 molecules and their uses
CA2415902A1 (en) * 2000-07-10 2002-01-17 Xencor Protein design automation for designing protein libraries with altered immunogenicity
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
CA2461351C (en) 2001-09-26 2014-08-05 Ira H. Pastan Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
CA2466443A1 (en) 2001-11-09 2003-05-15 Neopharm, Inc. Selective treatment of il-13 expressing tumors
ES2343965T3 (es) 2003-11-25 2010-08-13 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anticuerpos anti-cd22 e inmunocongujados mutados.
WO2009014650A2 (en) * 2007-07-20 2009-01-29 The General Hospital Corporation Recombinant vibrio cholerae exotoxins
EP2197903B9 (en) * 2007-09-04 2015-04-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
AU2010230063B2 (en) * 2009-03-24 2015-06-25 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
WO2011031441A1 (en) * 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
CA2773665C (en) * 2009-09-11 2018-02-20 Ira H. Pastan Improved pseudomonas exotoxin a with reduced immunogenicity
EP2576620A1 (en) * 2010-05-26 2013-04-10 Regents Of The University Of Minnesota Single -chain variable fragment anti-cd133 antibodies and uses thereof
KR20140033391A (ko) * 2011-06-09 2014-03-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 면역원성이 보다 낮은 t 세포 및/또는 b 세포 에피토프를 갖는 슈도모나스 외독소 a

Also Published As

Publication number Publication date
EP2311854A1 (en) 2011-04-20
EP2311854B1 (en) 2013-04-17
EP2332970A2 (en) 2011-06-15
PL3006458T3 (pl) 2018-05-30
CA2616987C (en) 2016-10-11
US20090142341A1 (en) 2009-06-04
EP3006456B1 (en) 2018-09-19
EP3006457B1 (en) 2017-11-22
EP3006457A1 (en) 2016-04-13
EP2332970A3 (en) 2011-09-14
ES2372537T3 (es) 2012-01-23
ES2410783T3 (es) 2013-07-03
CA2941466C (en) 2019-12-03
EP3006458A1 (en) 2016-04-13
PL3006456T3 (pl) 2019-05-31
EP1910407A2 (en) 2008-04-16
US8907060B2 (en) 2014-12-09
AU2006275865B2 (en) 2012-06-28
EP2332970B1 (en) 2015-12-23
CA2616987A1 (en) 2007-02-08
EP1910407B1 (en) 2011-09-14
ES2660026T3 (es) 2018-03-20
EP3006458B1 (en) 2017-11-22
EP3006456A1 (en) 2016-04-13
AU2006275865A1 (en) 2007-02-08
CA2941466A1 (en) 2007-02-08
ES2702650T3 (es) 2019-03-04
PL3006457T3 (pl) 2018-05-30
WO2007016150A3 (en) 2007-08-09
WO2007016150A2 (en) 2007-02-08
ATE524489T1 (de) 2011-09-15
ES2659039T3 (es) 2018-03-13

Similar Documents

Publication Publication Date Title
US6147203A (en) Recombinant disulfide-stabilized polypeptide fragments having binding specificity
Chaudhary et al. A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.
ES2362386T3 (es) Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
ES2659039T3 (es) Exotoxinas de pseudomonas mutadas con antigenicidad reducida
CN105477641B (zh) 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途
Malins et al. Peptide ligation–desulfurization chemistry at arginine
ES2985999T3 (es) Conjugados de proteínas
US7906624B2 (en) Binding peptidomimetics and uses of the same
ES2870802T3 (es) Métodos de replegado de proteínas a elevado pH
Liu et al. Enabling chemical protein (semi) synthesis via reducible solubilizing tags (RSTs)
KR20030081315A (ko) 화학적으로 합성한 폴리펩티드의 폴딩 방법
ES2813501T3 (es) Métodos de replegado de proteínas basados en filtración de flujo tangencial
US11345745B2 (en) Peptide-hinge-free flexible antibody-like molecule
Brinkmann et al. Stabilization of a recombinant Fv fragment bybase-loop interconnection and VH-VL permutation
KR20180089433A (ko) 부위-특이적 접합을 위한 변이체 항체
Lu et al. A de novo designed template for generating conformation-specific antibodies that recognize α-helices in proteins
Singh Surface plasmon resonance (SPR) based binding studies of refolded single chain antibody fragments
Martin et al. Engineering novel bioactive mini-proteins on natural scaffolds
Katayama et al. Application of 2, 2′‐dipyridyl disulfide‐mediated thiazolidine ring‐opening reaction to glycoprotein synthesis: Total chemical synthesis of evasin‐3
KR102140557B1 (ko) 단백질-단백질 결합체를 형성 매개 펩타이드 및 이를 이용한 단백질-단백질 결합체 형성 방법
Whitlow Protein Engineering Strategies
JP2020511519A (ja) 操作された安定なｃｈ２ポリペプチド
Kim et al. Activation of a refolded, berberine-specific, single-chain Fv fragment by addition of free berberine
BRErrLING et al. Fv Fragments with C-Terminal Cysteines
MUYLDERMANS et al. Wheat germ in vitro translation to produce one of the most toxic sodium channel specific toxins